Multiple benefits of targeting inflammation in the treatment of type 2 diabetes.
Diabetologia
; 59(4): 679-82, 2016 Apr.
Article
em En
| MEDLINE
| ID: mdl-26868493
ABSTRACT
The association between the metabolic syndrome and a pathological activation of the innate immune system is now well established. Thus, defective insulin secretion and action are due, at least in part, to islet, liver and fat inflammation in type 2 diabetes. Furthermore, an inflammatory process also seems to be involved in the development of cardiovascular, renal and ophthalmological complications of this disease. Interestingly, several other inflammatory diseases are associated with the metabolic syndrome, such as psoriasis, gout and rheumatic arthritis. The aim of this review is to discuss the clinical progress of anti-inflammatory drugs in the treatment of type 2 diabetes and then speculate on the possible further development of these drugs, with the aim of using the drugs in combination in order to combat the multiple manifestations of inflammatory diseases. This review summarises a presentation given at the 'Islet inflammation in type 2 diabetes' symposium at the 2015 annual meeting of the EASD. It is accompanied by two other reviews on topics from this symposium (by Simone Baltrusch, DOI 10.1007/s00125-016-3891-x , and Jerry Nadler and colleagues, DOI 10.1007/s00125-016-3890-y ) and a commentary by the Session Chair, Piero Marchetti (DOI 10.1007/s00125-016-3875-x ).
Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Diabetes Mellitus Tipo 2
/
Inflamação
Limite:
Humans
Idioma:
En
Ano de publicação:
2016
Tipo de documento:
Article